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Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an
exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induced platelet CD62P
expression. However, VacA reacted with none of the alleged VacA receptors present on platelet membranes. We
therefore analyzed VacA associated proteins obtained through VacA affinity chromatography, using MALDI-TOF-MS.
Multimerin1 was detected in two consecutive experiments, as the binding protein for VacA. Plasmon resonance
confirmed their binding, and dot blot analysis revealed that the peptide sequence AA 321-340 of multimerin 1 is
the binding site for VacA. In conclusion, we propose a new interaction between multimerin1 and VacA , which may
give another insight into H. pylori-induced platelet activations under H. pylori infection.
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Immune thrombocytopenia purpura (ITP) is an auto-
immune disorder caused by increased platelet clearance
by anti-platelet autoantibodies [1]. The prevalence of
Helicobacter pylori (H. pylori) infection on ITP patients
was 65% from 25 papers (in the range of 21.6% - 90.6%)
[2]. In 1998, Gasbarrini et al. reported that successful
eradication of H. pylori is followed by recovery of platelet
counts in ITP patients infected with this bacterium [3].
An accumulating body of evidence suggests that the
eradication of H. pylori is indeed effective in increasing the
platelet count in nearly half of H. pylori–infected patients
with ITP [2].
While the mechanism by which H. pylori induces
thrombocytopenia remains largely undetermined, there are
several lines of evidence to suggest that its infection acti-
vates platelets. Platelet aggregate formation was observed
in mice infected with H. pylori [4]. H. pylori infection
induces CD62P surface expression of platelets both in mice
and humans [4], and its eradication led to a decrease in
CD62P surface expression in ITP patients with H. pylori
infection [5]. Although there are reports to suggest that* Correspondence: yozaki@yamanashi.ac.jp
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reproduction in any medium, provided the orthe bacteria activate platelets by directly interacting
with platelet membrane proteins [6], it appears more
feasible that certain products of H. pylori circulate in
blood stream to interact with platelets, since H. pylori nests
in gastric mucosa where there could be no extensive inter-
action between the bacteria and platelets. In agreement
with this hypothesis, H. pylori water extracts induce the
formation of circulating platelet aggregates in rat gastric
mucosal microvessels [7].
H. pylori is equipped with a set of remarkable pathogenic
factors, including the cytotoxin-associated antigen (CagA)
and the vacuolating toxin A (VacA). The type IV secretion
system (T4SS) serves to translocate CagA directly into host
cells [8]. When delivered into gastric epithelial cells via
T4SS, H. pylori CagA perturbs host cell signaling and
thereby promotes disturbance of epithelium cells and gas-
tric carcinogenesis. By nature, it is an endotoxin, which is
not secreted into the milieu. The vacuolating cytotoxin,
VacA, induces cellular vacuolation in epithelial cells [9].
VacA is produced as a 140 kDa precursor protein and ac-
tively secreted from H. pylori by a type V autotransporter
mechanism [10]. The 87-95 kDa mature toxin is generated
by proteolytic cleavage of a 140 kDa precursor at the bac-
terial outer membrane [11,12]. Thus, we hypothesized that
if H. pylori secretes some substance which interacts with
platelets, VacA could be one of the most likely candidates.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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platelet activation, and attempted to identify the target
protein with which VacA interacts.
Materials and methods
This study complied with the Declaration of Helsinki and
was approved by the ethics committee of the University of
Yamanashi. Informed consent was obtained from all pa-
tients and healthy volunteers prior to the index procedure.
Materials
Glutathione S-transferase (GST)-fusion protein of multi-
nerin 1 (GST-MMRN1) was purchased from Abnova Cor-
poration (Taipei, Taiwan). Phycoerythrin (PE)–conjugated
anti-CD62P and mouse IgG1 control were from BD Biosci-
ences (CA, USA). HRP-conjugated goat anti-rabbit IgG
were from Santa Cruz Biotechnology (CA, USA). Syn-
thetic-peptides (Table 1) were made by Operon Biotech-
nologies (Tokyo, Japan) on our order. The 8% to 16%
gradient gel (sodium dodecyl sulfate–polyacrylamide gel
electrophoresis [SDS-PAGE]) was from TEFCO (Tokyo,
Japan). Colloidal gold staining kit was from Bio-Rad
Laboratories (CA, USA).
Study population
Patients, >18 years old, presenting with dyspepsia and/or
other symptoms suggestive of peptic ulcer diseases were re-
cruited for this study between January 1999 and September
2000 in the department of first internal medicine, Univer-
sity of Yamanashi Hospital.
Active H. pylori infection was assessed by 13C urea breath
test (UBT) in all recruited patients. Eighteen patients were
UBT test negative, and 17 patients were UBT test positive.
H. pylori - infected patients underwent bacterial eradication
with the standard triple therapy: amoxicillin, clarithromycin
and lansoprazol for one week. Eradication was assessed by
UBT 4 to 6 weeks after treatment. Complete eradication
was observed with five patients.
Preparation of purified VacA
The toxin-producing strain H. pylori ATCC49503 was used
as the source of VacA for purification according to our







7 KSINVLIRDI (381-390)from culture supernatant with 50% saturated ammonium
sulfate. Precipitated proteins were dialyzed and then
applied to an anti-VacA-specific IgG antibody affinity
column. VacA was eluted from the affinity column under
acidic conditions. VacA was activated by the acidic elution.
VacA was inactivated on 95°C at 10 minutes (Heat-inacti-
vated VacA; H-VacA). Purified VacA and H-VacA were
stored at -80°C.
Platelet preparation
Venous blood collected from healthy drug-free volunteers
or patients was collected into 10% sodium citrate (3.8%
sodium citrate, wt/vol). Platelet-rich plasma (PRP) was
obtained after centrifugation at 150 g for 12 minutes.
Washed platelets were obtained by centrifugation as
previously described [14], using prostacyclin to prevent
platelet activation during the isolation procedure.
Pull-down with VacA-coated beads
Purified VacA was covalently coupled to cyanogen bromide
(CNBr)–activated Sepharose 4B beads (Amersham Biosci-
ences, Piscataway, NJ) according to the manufacturer’s
instructions. Glycine-coated beads were used as a negative
control. Surface proteins of washed platelets were la-
beled with biotin using ECL Protein Biotinylation System
(Amersham Biosciences). One milliliter biotin-labeled or -
unlabeled washed platelets (1 × 109/mL) was lysed by an
equal volume of 2 × ice-cold lysis buffer [14] and precleared
by 200 μL Sepharose 4B (50% slurry) for 1 hour. After the
detergent-insoluble debris was cleared by centrifugation at
15,000 g for 10 minutes, the supernatant was incubated
with 200 μL VacA-bound or glycine-bound Sepharose
4B for 2 hours at 4°C. The beads were washed 5 times in
1 × lysis buffer, and proteins were eluted from the beads
with 40 μL of SDS–reducing sample buffer and boiled
for 5 minutes.
Protein digestion and mass spectrometric analysis was
entrusted to Protein Research Network, Inc. (Yokohama,
Japan), and the database search was performed.
Flow cytometric analysis
PRP (2 × 108/mL) were incubated with 120 nM VacA
or H-VacA for 30 minutes followed by staining with
anti-CD62P-PE or mouse IgG1-PE Platelet Control for
20 minutes at room temperature in the dark. Platelets were
mixed with 1% paraformaldehyde in phosphate-buffered
saline (PBS) for 20 minutes, and samples were analyzed
with a FACScan flow cytometer and CellQuest software
(Becton Dickinson, CA, USA).
VacA-MMRN1 binding assay(Dot-blot)
Synthesized peptides (Table 1) corresponding to the
amino acid sequence 291-390 of MMRN1 were dissolved
in saline and 2.5 μL (5 mM) of each peptide was spotted
Figure 1 VacA induces CD62P expression on platelets. PRP were
incubated with 120nM VacA or H-VacA. After 30 minutes, PRP were
staining with anti-CD62PE or mouse control IgG1-PE for 20 minutes in
the dark. Platelets were mixed with 1% paraformaldehyde in PBS, and
samples were analyzed with a flow cytometer. The data expressed as
per cent increase over the control are compiled from 6 experiments.
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with three times with TBS-T (Tris-buffered saline contain-
ing 0.1% Tween 20) and incubated with 1% bovine serum
albumin for 1 h at room temperature. The membrane was
incubated first with 10 ng/mL of VacA, secondly with
100 ng/mL of anti-VacA polyclonal antibody and then
with HRP-conjugated anti-rabbit antibody, respectively,
for 1 h at room temperature with gentle agitation. It was
washed three times with TBS-T after each incubation step.
Antibody binding was visualized with ECL Western
Blotting Detection Reagents (GE Healthcare, UK).
Surface plasmon resonance measurement
Specific interactions between VacA and GST-MMRN1
were analyzed using BIAcore X system (BIAcore, Uppsala,
Sweden) at 25°C. GST-MMRN1 was covalently coupled
to CM5 chip (BIAcore) using an Amine Coupling Kit
(BIAcore) according to the manufacturer’s instructions.
Regeneration of the protein-coated surfaces was achieved
by running 10 μL of 10 mM NaOH through the flow cell at
the rate of 10 μL/min 2 times. A control surface was
reacted with the amine coupling reagent in the absence of
ligand and then blocked with ethanolamine. Various con-
centrations of VacA in PBS with 1 mM Ca++ was perfused
over the control surface or immobilized GST-MMRN1
surfaces at a flow rate of 20 μL/min, and the resonance
changes were recorded. The sensorgram of the immobilized
GST-MMRN1 surfaces was subtracted from that of the
control surfaces and the dissociation constants (KD) was
determined using the BIAevaluation software (BIAcore).
Statistics
Statistical analysis was performed using the paired Student’s
t test. P values of less than 0.05 were taken as the minimum
to indicate statistical significance.
Results
CD62P expression in platelets
We carried out a small-size clinical study at our university
to evaluate the CD62P expression in platelets from patients
with dyspepsia and/or other symptoms suggestive of peptic
ulcer diseases. The CD62P expression in platelets was
1.5 ±3.9% in patients free from H. pylori infection (n = 18).
However, its expression was significantly increased to
9.5 ±8.1% with H. pylori infection (n = 17, p < 0.001), and
with those who underwent eradication successfully (n = 5),
the CD62P expression was significantly lowered (1.9 ± 0.8%,
p < 0.02). These findings were in good agreement with the
previous reports [4,5] and we were led to assume that plate-
lets are activated by the presence of H. pylori. Although
there are reports to suggest that platelet aggregation is
induced by the bacterial body of H. pylori, there has been
no report to show the presence of circulating H. pylori in
blood stream, apart from the gastric mucosa. Thus, it islikely that some molecules produced by H. pylori move into
circulation, and activate platelets. In this line of reasoning,
we next cultured H. pylori, and evaluated the effects of the
culture supernatant on CD62P expression in platelets.
As we expected, the culture supernants of H. pylori
induced the expression of CD62P in platelets from healthy
individuals (data not shown).
The effects of VacA on platelet functions
Of the toxins produced by H. pylori, CagA, an endotoxin, is
injected into the cytoplasm of target cells by the type IV
secretory apparatus. We thus speculated that VacA, an exo-
toxin released by H. pylori, is responsible for the platelet-
activating effects of the culture supernatant, and sought to
evaluate the effects of VacA on platelet functions.
VacA did not induce platelet aggregation, when
added to PRP (data not shown). However, it increased
the expression of CD62P upon interaction with plate-
lets (Figure 1). VacA, which is incubated at 95°C for
10 minutes, loses the vacuole-forming activity and the
binding capacity to RPTPβ [15]. Heat-inactivated VacA
(H-VacA) thus prepared did not significantly increase
CD62P expression in platelets over the control, suggesting
that VacA activates platelets by its biological activity, and
that VacA interacts with its corresponding receptors on
the platelet membrane for platelet activation.
Exploration for the VacA receptor
The findings hitherto suggested that there is a specific
receptor on the platelet membranes for VacA. Four cell
Figure 2 Pull-down assay for detection of VacA binding protein(s).
Purified VacA was covalently coupled to CNBr-beads. Glycine-coated
CNBr-beads were used as a negative control. Surface proteins in
washed platelets were labeled with biotin. Platelets lysate was
incubated with VacA bound or glycine bound beads. The beads
were washed in lysis buffer, and proteins were eluted from the
beads with SDS-reducing sample buffer. Eluted proteins were
separated on SDS-PAGE, electroblotted, and proved with avidin-HRP
(Figure 2) or with colloidal gold staining (data not shown). Left VacA
beads, Right glycine beads.
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receptors for VacA, including EGFR [16], RPTPα [17],
RPTPβ [15,18] and CD18 [19]. CD18 is reportedly
expressed in platelets [20]. However, the expression of
RPTPα and RPTPβ, or EGFR, which is ordinarily expressed
in the epithelial cell lineage, on the platelet membrane,
remains unknown. We therefore evaluated the expression
of these four VacA receptors on platelets by using the
corresponding antibodies and Western blotting. We found
that RPTPβ and CD18 were expressed on the platelet
membrane. However, we were not able to detect the
binding between VacA and each of these receptors with the
use of either anti-VacA antibody or the antibody against
each of these receptors. Based on these findings, we
assumed that there is a receptor for VacA distinct from
RPTPβ or CD18, which leads to platelet activation.
We next sought to identify the VacA-binding protein,
using VacA affinity beads. Briefly, the proteins on the
platelet membrane were biotin-labeled, and then solubi-
lized by detergents. The lysates were reacted with VacA
affinity beads, and after washing of the beads several
times, the proteins were removed from the beads with
the addition of SDS sample buffer. They were analyzed
with SDS-PAGE, and after comparison with the glycine
beads as the control, the protein bands specific for VacA
affinity beads were identified. There were p40, p50, p55,
p80, p120, and p175 bands, (Figure 2). All the bands were
further analyzed by the peptide mass fingerprinting
method, using MALDI-TOF-MS. As a result, a set of
the peptides matched from the database suggested that
multimerin 1 (MMRN1) was present in p175 (Figure 3).
Previously reported VacA receptors (EGFR, RPTPα,
RPTPβ, CD18) were not detected from any bands. The
experiment was repeated twice with the same result,
which suggested that the target protein for VacA on the
platelet membrane is MMRN1.
A GST-fusion protein of MMRN1 corresponding to
the 291a.a. ~ 391a.a peptide sequence was commercially
available. We checked with pulldown assay whether this
GST-MMRN1 also reacted with VacA, which turned out
to be the case. We utilized this protein for spotting the
VacA-binding site with a Biacore based on the principle
of surface plasmon resonance. First, we determined the
binding affinity between VacA and GST-MMRN1, with
GST-MMRN1 fixed on the measurement chip and various
concentrations of VacA as eluate. There was a concentra-
tion-dependent binding (Figure 4), with the dissociation
constant (KD) value of 3.3 x 10-8 (M), which suggests that
VacA binds to MMRN1 with an affinity similar to that
of antigen-antibody binding whose KD falls in the rage
of 10-7 ~ 10-9 (M) [21].
Since the GST-fusion protein of MMRN1 corresponding
to the 291a.a. ~ 391a.a peptide sequence is recognized by
VacA, there should be the binding site for VacA withinthis sequence. We synthesized the 20-aa-length peptides,
which partly overlap with one another (Table 1), and
checked the binding of VacA with the dot blot method
(Figure 5). As a result, the peptide sequence corresponding
to 321a.a. ~ 340a.a. showed the highest reactivity to VacA,
suggesting that VacA binds to MMRN1 by interacting with
this region.
Discussion
Recently, it has been suggested that H. pylori infection
contributes to the pathogenesis of ITP, since partial or
even complete remission of thrombocytopenia has been
reported in a considerable portion of patients after eradi-
cation of H. pylori [2,22]. Some reports suggest the pro-
duction of cross-reactive autoantibodies between the
bacteria and platelets is responsible. In this line of rea-
soning, cross molecular mimicry between the H. pylori
CagA protein or urease B, and platelet antigens has been
implicated as a possible pathopysiological mechanism for
this subset of ITP [23,24]. It was also suggested that auto-
reactive CD4+ T cells to glycoprotein IIb-IIIa (GPIIb-IIIa)
mediate anti-platelet autoantibody production in patients
with ITP. However, immediate recovery of platelet counts
Figure 3 Mass spectrometric analysis of p175. p40, p50, p55, p80, p120 and p175 proteins in Figure 2 were excised and digested with
endoproteinase Lys-C and analyzed by Mass spectrometry. The resulting peptide sequences matched with those of multimerin 1.
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autoantibody production hypothesis, since it may persist
for some time after the disappearance of the antigen(s).
Another hypothesis which may better explain this phe-
nomenon is that platelet activation and/or apoptosis
induced by H. pylori itself and/or toxin(s) produced by
H. pylori, leads to a decrease in platelet counts which
then manifest as ITP. A report suggests that the bacteria
activate platelets by directly interacting with GPIb, one of
the major platelet membrane proteins [6]. However, it is
more likely that certain products of H. pylori circulate
in blood to interact with platelets, since H. pylori nests
in gastric mucosa where there could be no extensive
interaction between the bacteria and platelets. In this
paper, we propose a new interaction between plateletsFigure 4 Typical trace of GST-MMRN1-VacA association and dissociati
Coupling Kit. A control surface was reacted with amine coupling reagent in
over the control surface and immobilized GST-MMRN1 surfaces, and the re
system (n=2).and H. pylori, which may give another insight into H.
pylori-induced ITP.
H. pylori infection induces CD62P surface expression
of platelets both in mice and humans [4], a marker of
platelet activation, and its eradication led to a decrease in
CD62P surface expression in ITP patients with H. pylori
infection [5]. However, the mechanism by which H. pylori
induces platelet activation has remained unknown. In a
series of preliminary experiments, we found that the
culture supernatant of H. pylori induced the expression
of CD62P in platelets, suggesting that some proteins
(toxins) produced by H. pylori is responsible for this
phenomenon. Since CagA, a most well-known toxin of
H. pylori should be injected into the cytoplasm of target
cells by a specific secretory apparatus, we speculated thaton. GST-MMRN1 was covalently coupled to CM5 chip using an Amine
the absence of ligand. Several concentrations of VacA was perfused
sonance changes were recorded and analysed with a BIAcore
Figure 5 VacA recognizes 321aa-340aa sequences. Synthesized peptides (Table 1) were dissolved in saline, and spotted on PVDF membrane.
VacA also spotted on PVDF membrane for the positive control. The membrane was incubated without VacA (VacA(-)), or with H-VacA or VacA.
The membrane was incubated with anti-VacA polyclonal antibody and then HRP-conjugated secondary antibody (n=3).
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activating platelets, and sought to evaluate the effects of
VacA on platelet functions.
VacA did not induce platelet aggregation, when added
to PRP (data not shown). However, as we expected, it did
induce the expression of CD62P upon addition to PRP.
Heat-inactivated VacA, which is incapable of vacuole
formation did not increase CD62P expression in platelets,
suggesting that VacA activates platelets by its biological
activity. These findings strongly suggest that there is a
specific receptor on the platelet membranes for VacA.
Four cell surface proteins have been implicated so far as
the specific receptors for VacA, including EGFR, RPTPα,
RPTPβ and CD18. We therefore evaluated the expression
of these four VacA receptors on platelets by Western
blotting, and detected RPTPβ and CD18 expression in
platelets (data not shown). However, we were not able to
detect the VacA-RPTPβ or VacA-CD18 binding with
the use of either anti-VacA antibody, anti- RPTPβ or
anti-CD18 antibodies. Thus, we drew a tentative conclu-
sion that there is a receptor for VacA distinct from RPTPβ
or CD18, which leads to platelet activation.
We sought to pinpoint the VacA-binding protein(s) on
the platelet membrane with VacA affinity chromatography
and the peptide mass finger printing method. As a result,
two consecutive experiments both identified MMRN1
as a target protein for VacA. MMRN1 is a massive, ho-
mopolymeric adhensive protein, which belongs to the
family of the Elastin-Microfibril Interface Located proteins
(EMLIN). MMRN1 is the only EMILIN protein expressed
in the megakaryocytic lineage, based on proteome andtranscriptome analysis. It is stored in the secretion granules
of megakaryocytes, platelets, and vascular endothelial cells
[25]. Following platelet activation, MMRN1 is released
from platelets and binds to activated platelet surface [26],
external membranes of endothelial cells, and extracellular
matrix.
Several lines of evidence have confirmed the interaction
between VacA and MMRN1. A commercially available
GST-fusion protein of partial MMRN1 (291aa-391aa)
interacts with VacA, assessed by the far-western blot
and the plasmon resonance analysis. We inquired of
the supplier the reason why the GST fusion of protein
of this specific sequence of MMRN1 was produced.
However, we were not able to obtain relevant information.
To the best of our knowledge, there has been no report
to refer the structural or functional significance of the
291aa-391aa sequence of MMRN1. We speculate that
the supplier estimated the most likely domain leading
to the effective antibody production, using a computer
software, and made the GST fusion protein encompassing
291aa ~ 391aa MMRN1 as the antigen. Commercial sup-
pliers of reagents often follow this process in order to
obtain antibodies to specific proteins. This hypothesis also
implies that this site is externally exposed. Using several
peptides corresponding to this sequence of MMRN1,
we found that the 321aa ~ 340aa peptide of MMRN1
most strongly reacts with VacA, which suggests that VacA
recognizes this sequence.
We hitherto found that VacA binds MMRN1, and that
its binding site for VacA appears to reside within the
321aa ~ 340aa sequence. However, how this translates
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Although we have no direct evidence at present, several
hypotheses could be postulated. MMRN1 is stored in
platelet α granules, and is considered to be an activation
marker, since it is released into extracellular milieu upon
platelet activation. However, it is likely that at least a
small amount of MMRN1 is already present on a certain
population of platelets, which are partially activated or
senescent, similar to platelet factor 4 (PF4). MMRN1
is known to bind αvβ3, αIIbβ3 and other unidentified
receptors on the platelet membrane [27]. VacA, by bind-
ing to MMRN1, may facilitate the interaction between
MMRN1 and these platelet activation receptors, with
resultant activation of platelets. Platelet activation should
lead to MMRN1 release and VacA-MMRN interaction,
and with the formation of this positive feedback, more
and more activated platelets may be sequestered with
the onset of ITP.
Alternatively, the interaction between MMRN1 and the
coagulation Factor V needs attention. MMRN1 is known
to bind Factor V and activated Factor V with high affinity,
and this binding appears to inhibit the coagulation cascade
[28]. If VacA binding to MMRN1 should have some effects
on Factor V inactivation by MMRN1, it may lead to en-
hanced thrombin generation, which would culminate
in platelet activation.
Finally, similar to the pathogenesis of heparin-induced
thrombocytopenia (HIT), in which the interaction between
PF4 and heparin exposes a new epitope on PF4, thereby in-
ducing the antibody production against the PF4-heparin
complex, VacA and MMRN1 interaction may also induce
the conformational change in MMRN1, exposing a new
epitope. This process may lead to the production of
antibodies, which activate platelets in a manner similar
to that of HIT antibodies.
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